Document:

exv10w61

 

Exhibit 10.61

ALLERGAN, INC.

2003 NONEMPLOYEE DIRECTOR EQUITY INCENTIVE PLAN

NON-QUALIFIED STOCK OPTION AWARD AGREEMENT

        This Non-qualified Stock Option Agreement (“Agreement”) is entered into as of May      , 20     ,
(the “Date of Grant”) between Allergan, Inc., a Delaware corporation (the “Company”), and
                                        , a director of the Company (the “Director”).

        The Company has adopted and the stockholders of the Company have approved the 2003 Nonemployee
Director Equity Incentive Plan, as amended (the “Plan”). Pursuant to Section 3.1 of the Plan and
in consideration of the services rendered and to be rendered by the Director, the Company has
granted an option to the Director upon the terms and conditions set forth in the Plan and this
Agreement.

        1.     Number of Option Shares. This Agreement evidences the grant by the Company to the Director
of a non-qualified stock option (the “Option”) to purchase, from time to time, an aggregate of
4,500 shares (the “Option Shares”) of the Company’s Common Stock, par value $0.01 per share (the
“Common Stock”), under Section 3.1 of the Plan, subject to the terms and conditions and to
adjustment as set forth herein or in the Plan.

        2.     Option Purchase Price. Upon exercise of vested Option Shares, the Director shall pay to
the Company $                     per Option Share (the “Option Purchase Price”) being exercised.

        3.     Option Expiration Date. Unless terminated sooner in accordance with the provisions of the
Plan or this Agreement, the right to exercise the Option shall expire on the close of business on
the business day immediately preceding the tenth (10th) anniversary of the Date of Grant
(the “Expiration Date”).

        4.     Vesting Restrictions. Subject to the provisions of Section 5 of this Agreement and to
adjustment pursuant to Section 4.2 of the Plan, the Option shall become fully vested and
exercisable as to all Option Shares on the one (1) year anniversary of the Date of Grant.

        5.     Effect of Certain Events on Vesting and Exercise.

                a.     Termination of Service.

                         (i)     General. If the Director ceases to serve as a director of the Company for any
reason other than such Director’s death or total disability, any portion of the Option that has not
vested as of such termination of service shall be forfeited.

                         (ii)     Termination as a Result of Death or Disability. If the Director ceases to serve
as a director of the Company by reason of such Director’s death or total disability, the Option
shall vest immediately as to the entire number of Option Shares.

                b.     Change of Control. Upon the occurrence of a Change of Control (as defined in Section 4.3
of the Plan), the Option shall vest immediately as to the entire number of Option Shares.

1

 

                c.     Exercise Period Following Termination of Service.

                         (i)     In the event the Director ceases to be a director by reason of such Director’s voluntary
resignation or removal for cause, any unexercised portion of the Option that is vested as of such
termination of service may be exercised by the Director at any time within three (3) months
following such termination of service, but in no event after the Expiration Date.

                         (ii)     In the event the Director ceases to be a director other than by reason of such Director’s
voluntary resignation or removal for cause, any unexercised portion of the Option that is vested as
of such termination of service may be exercised by the Director or by the Director’s personal
representative or by the person or persons to whom the Option shall have been transferred by will
or the laws of descent and distribution at any time within twelve (12) months following such
termination of service, but in no event after the Expiration Date.

        6.     Exercise of Option.

                a.     All or a portion of the vested Option may be exercised in accordance with procedures
(including requisite holding periods) established from time to time by the Board.

                b.     Payment of the aggregate Option Purchase Price for the number of vested Option Shares for
which the Option is being exercised shall be made (i) in cash or by check, (ii) by delivery of a
notice that the Director has placed a market sell order with a broker with respect to shares of
Common Stock then issuable upon exercise of the Option, and the broker pays a sufficient portion of
the net proceeds of the sale to the Company in satisfaction of the aggregate Option Purchase Price,
provided that the Company shall not deliver such shares until payment of such proceeds is received
by the Company, or (iii) by any combination of the foregoing. However, the Board of Directors may,
in its discretion, (x) allow payment, in whole or in part, through the delivery of shares of Common
Stock which have been owned by the Director for at least six (6) months, duly endorsed for transfer
to the Company with a Fair Market Value on the date of delivery equal to the aggregate Option
Purchase Price of the Option or exercised portion thereof, (y) allow payment, in whole or in part,
through the delivery of property of any kind which constitutes good and valuable consideration, or
(z) allow payment through any combination of the foregoing.

                c.     The Director agrees, with respect to the Option, to pay to the Company an amount sufficient
to satisfy any taxes or other amounts required by any governmental authority to be withheld and
paid over to such authority for his or her account, or to otherwise make arrangements satisfactory
to the Board for the payment of such amounts.

                d.     Subject to adjustment pursuant to Section 4.2 of the Plan, a minimum of six months shall
elapse between the Date of Grant and the sale of any of the Option Shares. No shares of Common
Stock shall be issued or transferred upon exercise of the Option unless and until all legal
requirements applicable to the issuance or transfer of such Common Stock have been complied with to
the satisfaction of the Board.

        7.     No Assignability. The Option is not assignable or transferable by the Director, except by
will or by the laws of descent and distribution and shall not be subject to any encumbrance, pledge
or charge of any nature. During the lifetime of the Director, the Option may be exercised only by
the Director or, if the Director becomes disabled, by the Director’s guardian or legal
representative. The restrictions on exercise and transfer shall not be deemed to prohibit, to the
extent permitted by the Board, transfers to any one or more Permitted Transferees (as defined
below), subject to the following terms and conditions: (i) the Option shall not be assignable or
transferable by the Permitted Transferee other than by will or the laws of descent and
distribution; (ii) the Option which is transferred to a Permitted Transferee shall continue to be
subject to all the terms and conditions of the Option as applicable to the Director (other than the

2

 

ability to further transfer the Option); and (iii) the Director and the Permitted Transferee
shall execute any and all documents requested by the Board, including, without limitation documents
to (x) confirm the status of the transferee as a Permitted Transferee, (y) satisfy any requirements
for an exemption for the transfer under applicable federal and state securities laws and (z)
evidence the transfer. For purposes of this Section 7, “Permitted Transferee” shall mean, with
respect to a Director, any child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the
Director’s household (other than a tenant or employee), a trust in which these persons (or the
Director) control the management of assets, and any other entity in which these persons (or the
Director) own more than fifty percent of the voting interests, or any other transferee specifically
approved by the Board after taking into account any state or federal tax or securities laws
applicable to transferable non-qualified stock options.

        8.     General Terms. The Director acknowledges receipt of a copy of the Plan and the Plan
Prospectus. The Option and this Agreement are subject to, and the Company and the Director agree
to be bound by, the provisions of the Plan and the Plan Prospectus that apply to the Option. Such
provisions are incorporated herein by this reference. In the event of a conflict between the terms
of this Agreement and the Plan, the Plan shall be the controlling document. Capitalized terms used
but not defined herein shall have the respective meanings ascribed to them in the Plan.

        9.      Other Provisions.

                a.     Neither the Director nor any other person entitled to exercise the Option shall have any
rights as a stockholder with respect to any Option Shares until the date the Director or such other
person becomes the holder of record of such Option Shares following exercise of the Option.

                b.     The Director acknowledges that the Company has the right to amend, suspend or terminate the
Plan in any respect whatsoever at any time (including, but not limited to, the power to amend the
number of shares subject to awards granted thereunder) except to the extent prohibited by law and
except that no such amendment, suspension or termination may, without the Director’s consent,
adversely affect the rights of the Director under the Option.

                c.     In the event that any provision this Agreement is held to be invalid, void or
unenforceable, the same shall not affect, in any respect whatsoever, the validity of any other
provision of this Agreement.

                d.     The rights and obligations under this Agreement shall inure to the benefit of, and shall be
binding upon, the Company and its successors and assignees and the Director and the Director’s
heirs, executors, administrators, personal representations, transferees, assignees and successors
in interest.

                e.     Any communication under this Agreement shall be in writing and addressed to the Company at
2525 Dupont Drive, Irvine, California 92612, Attention: General Counsel and to the Director at the
address given beneath the Director’s signature, or at such other address as either party may
hereafter designate in writing to the other.

                f.     The interpretation, performance and enforcement of the Option and this Agreement shall be
governed by the internal laws of the State of California.

3

 

                         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written.

	 	 	 	 	 	 	 
	 	 	THE COMPANY:
	 
	 	 	 	 	 	 
	 	 	ALLERGAN, INC.,
	 	 	a Delaware corporation
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 	 	 	 	 
	 

	 	 	 	 
	 	David E.I. Pyott,

Chairman of the Board and

Chief Executive Officer
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	DIRECTOR:
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 

4<PAGE>

                                                                         EX-10.3

================================================================================

                       THIRD WAVE TECHNOLOGIES JAPAN, K.K.

                  SERIES A PREFERRED STOCK AND WARRANT PURCHASE
                                    AGREEMENT

                                 MARCH 31, 2006

================================================================================

<PAGE>

                       THIRD WAVE TECHNOLOGIES JAPAN, K.K.

             SERIES A PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT

     This Series A Preferred Stock and Warrant Purchase Agreement (this
"AGREEMENT") is made as of March 31, 2006 (the "EFFECTIVE DATE"), by and among
Third Wave Technologies Japan, K.K., a Japanese corporation (the "COMPANY"), and
the persons and entities (each, an "INVESTOR" and collectively, the "INVESTORS")
listed on the Schedule of Investors attached as Exhibit A.

                                    SECTION 1

         AUTHORIZATION AND SALE OF SERIES A PREFERRED STOCK AND WARRANTS

     1.1 AUTHORIZATION. The Company will, prior to the Closing (as defined
below), authorize (a) the sale and issuance of up to 8,056 shares (the "SHARES")
of the Company's Series A Preferred Stock (the "SERIES A PREFERRED"), having the
rights, privileges, preferences and restrictions set forth in the Articles of
Incorporation of the Company, in substantially the form attached as Exhibit B,
and subject to possible post-Effective Date revisions by the Japanese Legal
Affairs Bureau (the "Bureau," and such Articles of Incorporation, the
"ARTICLES"); and (b) the issuance of warrants, with the terms set forth on as
Exhibit H, subject to possible post-Effective Date revisions by the Bureau (the
"WARRANTS"), for the purchase of up to 1,388 shares of the Company's Common
Stock (the "WARRANT SHARES").

     1.2 SALE AND ISSUANCE OF SHARES. Subject to the terms and conditions of
this Agreement, the Investors agree to purchase, and the Company agrees to sell
and issue to the Investors, the number of Shares set forth in the column
designated "Number of Series A Shares" opposite each such Investor's name on
Exhibit A, at a cash purchase price of Y71,996 per share, for an aggregate
purchase price of Y579,999,776 (the "PURCHASE PRICE").

     1.3 ISSUANCE OF WARRANTS. Subject to the terms and conditions of this
Agreement, the Investors agree to purchase, and the Company agrees to issue to
the Investors, a Warrant exercisable for the number of Warrant Shares set forth
in the column designated "Number of Warrant Shares" opposite each such
Investor's name on Exhibit A, each at an exercise price of Y71,996 per share,
for an aggregate exercise price of Y99,930,448 (the "EXERCISE PRICE").

     1.4 PAYMENT. Subject to Section 5, the Investors shall remit the Purchase
Price by wire transfer of immediately available funds to the subscription
account (betsudan yokin koza) designated by the Company to receive payment from
the Investors for the Shares (the "SUBSCRIPTION ACCOUNT"), to arrive on or
before April 10, 2006, or such other date as the parties may mutually agree. The
Company shall deliver to the Investors written wiring instructions for the
Subscription Account at least five (5) business days prior to the Closing Date
(as defined below).

<PAGE>

                                    SECTION 2

                             CLOSING DATES; DELIVERY

     2.1 CLOSING.

          (a) The purchase, sale and issuance of the Shares and the Warrants
(the "CLOSING") shall take place on April 10, 2006, or such other date as the
Company and the Investors shall agree (the "CLOSING DATE").

          (b) The Closing shall be held at the offices of Anderson Mori &
Tomotsune, Izumi Garden Tower, 1-6-1 Roppongi, Minato-ku, Tokyo, Japan, at 5:00
p.m. local time, on the Closing Date, or at such other time and place upon which
the Company and the Investors shall agree.

     2.2 DELIVERY. At the Closing, the Company will deliver to each Investor a
certificate registered in such Investor's name representing the number of Shares
that such Investor is purchasing against delivery to the Subscription Account of
the Purchase Price therefor, as set forth in the column designated "Purchase
Price" opposite such Investor's name on Exhibit A.

                                    SECTION 3

                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

     Except as set forth on the Schedule of Exceptions attached as Exhibit C
(the "SCHEDULE OF EXCEPTIONS") delivered to the Investors in connection with
this Agreement, the Company represents and warrants to the Investors as of the
date of this Agreement as follows:

     3.1 ORGANIZATION AND STANDING. The Company is a corporation duly
incorporated and existing under, and by virtue of, the laws of Japan. The
Company has the requisite corporate power and authority to own and operate its
properties and assets, and to carry on its business as presently conducted. The
Company is presently qualified to do business as a foreign corporation in each
jurisdiction where the failure to be so qualified could reasonably be expected
to have a material adverse effect on the Company's financial condition and
business as now conducted and proposed to be conducted (a "MATERIAL ADVERSE
EFFECT").

     3.2 CORPORATE POWER. Upon the Closing, the Company will have all requisite
legal and corporate power and authority to execute and deliver this Agreement,
the Investor Rights Agreement to be entered into by and among the Company, Third
Wave Technologies, Inc. (the "PARENT") and the Investors, in substantially the
form attached as Exhibit D (the "RIGHTS AGREEMENT"), to sell and issue the
Shares and the Warrants hereunder, to issue the Warrant Shares upon exercise of
the Warrants, to issue the shares of the Company's Common Stock issuable upon
conversion of the Shares, and to carry out and perform its obligations under the
terms of this Agreement and the Rights Agreement (together sometimes
collectively referred to herein as the "AGREEMENTS").

     3.3 SUBSIDIARIES. The Company does not own or control, directly or
indirectly, any interest in any corporation, partnership, limited liability
company, association or other business entity.

                                      -2-

<PAGE>

     3.4 CAPITALIZATION.(a) The authorized capital stock of the Company consists
or will, upon the Closing, consist of 160,000 shares of Common Stock, of which
40,000 shares are issued and outstanding as of the date of this Agreement, all
of which are beneficially owned by Third Wave Technologies, Inc., and 8,056
shares of Preferred Stock, all of which are designated Series A Preferred and
none of which are issued and outstanding prior to the Closing. The Common Stock
and the Series A Preferred shall have the rights, preferences, privileges and
restrictions set forth in the Articles.

          (b) The outstanding shares have been duly authorized and validly
issued in compliance with applicable laws, and are fully paid and nonassessable.

          (c) The Company has reserved:

               (i) 8,056 shares of Series A Preferred for issuance pursuant to
this Agreement;

               (ii) 1,388 shares of Common Stock for issuance upon conversion of
the Series A Preferred and upon exercise of the Warrants.

               (iii) 8,820 shares of Common Stock authorized for issuance to
employees, consultants and directors pursuant to stock options

          (d) The Shares, when issued and delivered and paid for in compliance
with the provisions of this Agreement will be validly issued, and will be fully
paid and nonassessable. The Common Stock issuable upon conversion of the Shares
(the "CONVERSION SHARES") and the Warrant Shares have been duly and validly
reserved and, when issued in compliance with the provisions of this Agreement,
the Articles and applicable law, and in the case of the Warrant Shares, in
compliance with the provisions of the Warrants, will be validly issued, and will
be fully paid and nonassessable. The Shares, the Warrants, the Warrant Shares
and the Conversion Shares will be free of any liens or encumbrances, other than
any liens or encumbrances created by or imposed upon the Investors; provided,
however, that the Shares, the Warrants, the Warrant Shares and the Conversion
Shares are subject to restrictions on transfer as set forth herein and in the
Rights Agreement. Except as set forth in the Rights Agreement, the Shares, the
Warrants, the Warrant Shares and the Conversion Shares are not subject to any
preemptive rights or rights of first refusal.

          (e) Except for the conversion privileges of the Series A Preferred,
the rights provided pursuant to the Rights Agreement or as otherwise set forth
herein, and except for the Warrants, there are no options, warrants or other
rights to purchase any of the Company's authorized and unissued capital stock.

     3.5 AUTHORIZATION. All corporate action on the part of the Company, its
directors and its shareholders necessary for the authorization, execution,
delivery and performance of the Agreements by the Company; the authorization,
sale, issuance and delivery of the Shares, the Warrants, the Warrant Shares and
the Conversion Shares; and the performance of all of the Company's obligations
under the Agreements has been taken or will be taken prior to the Closing. The
Agreements, when executed and delivered by the Company, shall constitute valid
and binding

                                      -3-

<PAGE>

obligations of the Company, enforceable in accordance with their terms, except
(i) as limited by laws of general application relating to bankruptcy,
insolvency, reorganization, moratorium, and other laws of general application
affecting enforcement of creditors' rights generally and the relief of debtors,
and (ii) as limited by rules of law governing specific performance, injunctive
relief or other equitable remedies and by general principles of equity.

     3.6 FINANCIAL STATEMENTS. The Company has delivered to the Investors its
unaudited balance sheet and statement of operations for the period ended
December 31, 2004 (the "FINANCIAL STATEMENTS"). The Financial Statements are
correct in all material respects and present fairly the financial condition and
operating results of the Company as of the date(s) and during the period(s)
indicated.

     3.7 CHANGES. To the Company's knowledge, since December 31, 2004, there has
not been any event or condition that has had a Material Adverse Effect.

     3.8 MATERIAL OBLIGATIONS. The Company has no material liabilities or
obligations, absolute or contingent (individually or in the aggregate), except
(i) liabilities and obligations which have been incurred in the ordinary course
of business which have not been, in any case, material (ii) liabilities and
obligations reflected in the Financial Statements, and (iii) obligations under
contracts and commitments incurred in the ordinary course of business and not
required under GAAP to be reflected in the Financial Statements.

     3.9 MATERIAL CONTRACTS. Section 3.9 of the Schedule of Exceptions sets
forth all contracts, agreements and instruments to which the Company is a party
or by which it is bound that involve (i) obligations of, or payments to, the
Company in excess of Y10,000,000, or (ii) the license of any patent,
copyright, trade secret or other proprietary right to or from the Company (the
"MATERIAL CONTRACTS"). To the Company's knowledge, all of the Material Contracts
are valid, binding and in full force and effect in all material respects,
subject to laws of general application relating to bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application affecting
enforcement of creditors' rights generally and the relief of debtors, and rules
of law governing specific performance, injunctive relief or other equitable
remedies and to general principles of equity. To the Company's knowledge, the
Company is not in material default under any of such Material Contracts

     3.10 INTELLECTUAL PROPERTY.

          (a) To the Company's knowledge (without having conducted any special
investigation or patent search), the Company owns or possesses sufficient legal
rights to all patents, trademarks, service marks, trade names, copyrights, trade
secrets, licenses (software or otherwise), product processes and similar
proprietary rights relating to any of the foregoing ("INTELLECTUAL PROPERTY")
necessary to the business of the Company as presently conducted, the lack of
which could reasonably be expected to have a Material Adverse Effect, without
any conflict with or infringement of the rights of others. Section 3.10(a) of
the Schedule of Exceptions contains a complete list of the Company's patents,
trademarks, copyrights and domain names and pending patent, trademark and
copyright applications. Except for agreements with its own employees or
consultants, standard end-user license agreements, support/maintenance
agreements and agreements

                                      -4-

<PAGE>

entered in the ordinary course of the Company's business, the Company is not
bound by or party to any outstanding options, licenses or agreements relating to
the foregoing and the Company is not bound by or a party to any options,
licenses or agreements with respect to the Intellectual Property of any other
person or entity. The Company has not received any written communication
alleging that the Company has violated any of the Intellectual Property of any
other person or entity. The Company is not obligated to make any payments by way
of royalties, fees or otherwise to any owner or licensor of or claimant to any
Intellectual Property with respect to the use thereof in connection with the
conduct of its business as presently conducted. There are no agreements,
understandings, instruments, contracts, judgments, orders or decrees to which
the Company is a party or by which it is bound which involve indemnification by
the Company with respect to infringements of Intellectual Property.

          (b) The Company is not aware that any of its employees are obligated
under any contract or other agreement, or subject to any judgment, decree or
order of any court or administrative agency, that would materially interfere
with the use of his or her efforts to promote the interests of the Company or
that would conflict with the Company's business as presently conducted. Neither
the execution nor delivery of this Agreement, nor the carrying on of the
Company's business by the employees of the Company, nor the conduct of the
Company's business as presently conducted, will, to the Company's knowledge,
conflict with or result in a breach of the terms, conditions or provisions of,
or constitute a default under, any contract, covenant or instrument under which
any of such employees is now obligated. The Company does not believe it is or
will be necessary to use any inventions of any of its employees made prior to
their employment by the Company.

          (c) Each founder, director with executive authority, employee and
consultant of the Company with access to confidential information of the Company
has executed a confidential information and invention assignment agreement,
substantially in the form(s) delivered to the Investors. Section 3.10(c) of the
Schedule of Exceptions contains a complete list of all founders and directors
with executive authority, employees and consultants of the Company with access
to confidential information of the Company. No such employee has excluded works
or inventions made prior to his or her employment with the Company from his or
her assignment of inventions pursuant to such employee's confidential
information and invention assignment agreement.

     3.11 TITLE TO PROPERTIES AND ASSETS; LIENS. The Company has good and
marketable title to its properties and assets, and has good title to all its
leasehold interests, in each case subject to no material mortgage, pledge, lien,
lease, encumbrance or charge, other than (i) for liens for current taxes not yet
due and payable, (ii) for liens imposed by law and incurred in the ordinary
course of business for obligations not past due, (iii) for liens in respect of
pledges or deposits under workers' compensation laws or similar legislation, and
(iv) possible minor liens, encumbrances and defects in title which do not in any
case materially detract from the value of the property subject thereto or
materially impair the operations of the Company, and which have not arisen
otherwise than in the ordinary course of business.

     3.12 COMPLIANCE WITH OTHER INSTRUMENTS. The Company is not in violation of
any material term of its Articles of Incorporation, as amended to date, or, to
the Company's knowledge,

                                      -5-

<PAGE>

in any material respect of any term or provision of any material mortgage,
indebtedness, indenture, contract, agreement, instrument, judgment, order or
decree to which it is party or by which it is bound. To the Company's knowledge,
the Company is not in violation of any statute, rule or regulation applicable to
the Company so as to have a Material Adverse Effect. To the Company's knowledge,
the execution, delivery and performance of and compliance with the Agreements,
and the issuance of the Shares, the Warrants, the Warrant Shares, and the
Conversion Shares, will not result in any material violation of, or materially
conflict with, or constitute a material default under, the Company's Articles of
Incorporation, as amended to date, or, to the Company's knowledge, any of its
material agreements, nor result in the creation of any material mortgage,
pledge, lien, encumbrance or charge upon any of the properties or assets of the
Company.

     3.13 LITIGATION. There are no actions, suits, proceedings or, to the
Company's knowledge, investigations pending against the Company or its
properties (nor has the Company received notice of any threat thereof) before
any court or governmental agency that, if determined adversely to the Company,
would have a Material Adverse Effect. The Company is not subject to the
provisions of any order, writ, injunction, judgment or decree of any court or
government agency or instrumentality.

     3.14 GOVERNMENTAL CONSENT. No consent, approval or authorization of or
designation, declaration or filing with any governmental authority on the part
of the Company is required in connection with the valid execution and delivery
of this Agreement, or the offer, sale or issuance of the Shares, the Warrants,
the Warrant Shares and the Conversion Shares, or the consummation of any other
transaction contemplated by this Agreement, except the filing of a securities
notice to be filed pursuant to the Securities and Exchange Law of Japan and
certain reports pursuant to the Foreign Exchange and Foreign Trade Law of Japan.

     3.15 OFFERING. The offer, sale and issuance of the Shares and the Warrants
to be issued in conformity with the terms of this Agreement, the issuance of the
Warrant Shares to be issued upon exercise of the Warrants and the issuance of
the Conversion Shares, constitute transactions exempt from the registration
requirements of the Japanese Securities and Exchange Law, as amended.

     3.16 TAX RETURNS AND PAYMENTS. The Company has filed all tax returns
required to be filed by it with appropriate governmental agencies, except where
the failure to do so would not have a Material Adverse Effect. All taxes shown
to be due and payable on such returns, any assessments imposed, and, to the
Company's knowledge, all other taxes due and payable by the Company on or before
the Closing have been paid or will be paid prior to the time they become
delinquent. The Company has not been advised in writing (i) that any of its
returns have been or are being audited as of the date hereof, or (ii) of any
deficiency in assessment or proposed judgment with respect to its federal, state
or local taxes.

     3.17 EMPLOYEES. To the Company's knowledge, there is no strike, labor
dispute or union organization activities pending or threatened between it and
its employees. None of the Company's employees belongs to any union or
collective bargaining unit.

                                      -6-

<PAGE>

     3.18 INSURANCE. The Company has in full force and effect fire and casualty
insurance policies and insurance against other hazards, risks and liabilities to
persons and property to the extent and in the manner customary for companies in
similar businesses similarly situated.

     3.19 PERMITS. The Company has all permits and licenses necessary for the
conduct of its business as currently conducted, and the Company believes it can
obtain, without undue burden or expense, any similar authority for the conduct
of its business as planned to be conducted. The Company is not in default under
any such permit or license.

     3.20 ENVIRONMENTAL AND SAFETY LAWS. To the Company's knowledge, the Company
is not in violation of any applicable statute, law or regulation relating to the
environment or occupational health and safety, and no material expenditures are
or will be required in order to comply with any such existing statute, law or
regulation.

     3.21 MINUTE BOOKS. The minute books of the Company contain a materially
complete summary of all meetings of directors and shareholders since the time of
incorporation and reflect all transactions referred to in such minutes
accurately in all material respects.

     3.22 USE OF PROCEEDS. The net proceeds to be paid to the Company at the
Closing are to be used for general working capital purposes in accordance with
the Company's annual budget as approved by the board of directors of the
Company. Except in connection with acquisition transactions, repurchases of
shares for use in a stock option plan that has been duly approved by the
Company's shareholders, or where it has been outlined by the Company to and
approved by the Investors, no proceeds will be used in the payment of any funded
debt of the Company or in the repurchase or cancellation of securities held by
any shareholder.

     3.23 DISCLOSURE. The Company has provided each Investor with all the
information reasonably available to it without undue expense that such Investor
has requested for deciding whether to purchase the Shares. To the Company's
knowledge, neither the Agreements nor any other documents or certificates
delivered in connection herewith, including but not limited to the Company's
business plan dated November 2, 2005, when taken as a whole, contains any untrue
statement of a material fact or omits to state a material fact necessary to make
the statements contained herein or therein not misleading in light of the
circumstances under which they were made. The Company does not represent or
warrant that it will achieve any financial projections provided to the Investors
and represents only that such projections were prepared in good faith.

                                    SECTION 4

                 REPRESENTATIONS AND WARRANTIES OF THE INVESTORS

     Each Investor severally represents and warrants to the Company with respect
to the purchase of the Shares, the Warrants, the Warrant Shares and the
Conversion Shares as follows:

     4.1 AUTHORIZATION.

          (a) Such Investor has all requisite power and authority to execute and
deliver the Agreements, to purchase the Shares and the Warrants hereunder and to
carry out and perform its obligations under the terms of the Agreements. All
action on the part of the Investor

                                      -7-

<PAGE>

necessary for the authorization, execution, delivery and performance of the
Agreements, and the performance of all of the Investor's obligations under the
Agreements, has been taken or will be taken prior to the Closing.

          (b) The Agreements, when executed and delivered by such Investor, will
constitute valid and legally binding obligations of the Investor, enforceable in
accordance with their terms except: (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors' rights generally, and (ii) as limited by
laws relating to the availability of specific performance, injunctive relief or
other equitable remedies or by general principles of equity.

          (c) No consent, approval, authorization, order, filing, registration
or qualification of or with any court, governmental authority or third person is
required to be obtained by the Investor in connection with the execution and
delivery of the Agreements or the performance of the Investor's obligations
hereunder or thereunder.

     4.2 LEGENDS. Such Investor understands and agrees that the certificates
evidencing the Shares, the Warrant Shares or any Conversion Shares, or any other
securities issued in respect of the Shares, the Warrant Shares or any Conversion
Shares upon any stock split, stock dividend, recapitalization, merger,
consolidation or similar event, shall bear the legends required by the other
agreements referenced or contemplated herein.

     4.3 PROJECTIONS Such Investor acknowledges and agrees that: (i) the Company
does not guarantee the accuracy of any financial projections or any estimates,
forecasts or plans provided in connections with the transactions contemplated
hereby, and (ii) the assumptions upon which the financial projections were based
relate to events over which the Company will have little or no control and that
actual results may be less attractive than the financial projections indicate.

     4.5 ACCORD WITH JAPANESE LAW. Such Investor represents that it has
satisfied itself as to the full observance of Japanese law in connection with
any invitation to subscribe for the Shares or any use of this Agreement,
including, without limitation, (i) Japanese legal requirements for the purchase
of Shares, (ii) any governmental or other consents that may need to be obtained,
and (iii) any income tax and other tax consequences, if any, that may be
relevant to the purchase, holding, redemption, sale or transfer of the Shares.
Such Investor's subscription and payment for, and its continued beneficial
ownership of the Shares, will not violate any applicable Japanese securities or
other laws.

                                    SECTION 5

                  CONDITIONS TO INVESTORS' OBLIGATIONS TO CLOSE

     An Investor's obligation to purchase the Shares and the Warrants at the
Closing is subject to the fulfillment on or before the Closing of each of the
following conditions, unless waived by the applicable Investor purchasing the
Shares and the Warrants:

                                      -8-

<PAGE>

     5.1 REPRESENTATIONS AND WARRANTIES. The representations and warranties made
by the Company in Section 3 (as modified by the disclosures on the Schedule of
Exceptions, as may be amended) shall be true and correct in all material
respects as of the Closing Date.

     5.2 COVENANTS. All covenants, agreements and conditions contained in this
Agreement to be performed by the Company on or prior to the Closing shall have
been performed or complied with in all material respects.

     5.3 SECURITIES LAW COMPLIANCE. The Company shall have obtained all
necessary securities law permits and qualifications, or have the availability of
exemptions therefrom, required by any governmental entity for the offer and sale
of the Shares, the Warrants, the Warrant Shares and the Conversion Shares.

     5.4 ARTICLES OF INCORPORATION. The Articles shall have been duly authorized
and executed to authorize the Shares, the Warrants, the Warrant Shares and the
Conversion Shares.

     5.5 RIGHTS AGREEMENT. The Company and the Parent shall have executed and
delivered the Rights Agreement in substantially the form attached as Exhibit D.

     5.6 AGREEMENT BETWEEN COMPANY AND PARENT. The Company and the Parent shall
have executed and delivered such agreement in substantially in the form attached
as Exhibit E.

     5.7 CONFIDENTIALITY AND INVENTION ASSIGNMENT AGREEMENTS. Each founder,
director with executive authority, employee and consultant of the Company listed
on Section 3.10(c) of the Schedule of Exceptions shall have executed a
confidentiality and invention assignment agreement, substantially in the form(s)
delivered to the Investors.

     5.8 DUE DILIGENCE REVIEW; APPROVAL. The Investors shall have completed due
diligence review to their satisfaction, including financial, legal, technical
and business due diligence, and the investment committees of the Investors shall
have approved the transactions contemplated hereunder.

     5.9 BUSINESS PLAN. The Company shall have prepared and delivered to the
Investors a detailed, comprehensive business plan and budget which includes an
explanation of the Company's intended use of the proceeds from the sale of the
Shares to the Investors.

     5.10 MANAGEMENT TEAM. The Company shall have identified, to the Investors'
reasonable satisfaction, core management candidates for the Company.

     5.11 CLOSING DELIVERABLES. The Company shall have delivered to counsel to
the Investors the following:

          (a) a certificate executed by the President of the Company on behalf
of the Company, in substantially the form attached as Exhibit F, certifying the
satisfaction of the conditions to closing listed in Sections 5.1 and 5.2; and

          (b) a certificate executed by a director of the Company on behalf of
the Company, in substantially the form attached as Exhibit G, attaching and
certifying to the truth and correctness

                                      -9-

<PAGE>

of the Articles, and certifying to the truth and correctness of the board and
shareholder resolutions adopted in connection with the transactions contemplated
by this Agreement.

                                    SECTION 6

                   CONDITIONS TO COMPANY'S OBLIGATION TO CLOSE

     The Company's obligation to sell and issue the Shares and the Warrants at
the Closing is subject to the fulfillment on or before the Closing of the
following conditions, unless waived by the Company:

     6.1 REPRESENTATIONS AND WARRANTIES. The representations and warranties made
by the Investors in Section 4 shall be true and correct in all material respects
as of the Closing Date.

     6.2 COVENANTS. All covenants, agreements and conditions contained in the
Agreements to be performed by Investors on or prior to the Closing shall have
been performed or complied with in all material respects.

     6.3 ARTICLES OF INCORPORATION. The Articles shall have been duly authorized
and executed to authorized the Shares, the Warrants, the Warrant Shares and the
Conversion Shares.

     6.4 RIGHTS AGREEMENT. The Investors shall have executed and delivered the
Rights Agreement in substantially the form attached as Exhibit D.

     6.5 PAYMENT OF PURCHASE PRICE. The Investors shall have delivered to the
Subscription Account the Purchase Price.

                                    SECTION 7

                                  MISCELLANEOUS

     7.1 AMENDMENT. Except as expressly provided herein, neither this Agreement
nor any term hereof may be amended, waived, discharged or terminated other than
by a written instrument referencing this Agreement and signed by the Company and
the Investors.

     7.2 NOTICES. All notices and other communications required or permitted
hereunder shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, sent by confirmed facsimile or otherwise delivered by
hand or by messenger addressed:

          (a) if to an Investor, at the Investor's address or facsimile number
as shown in the Company's records, as may be updated in accordance with the
provisions hereof; or

          (b) if to the Company, one copy should be sent to its address or
facsimile number set forth on the signature page of this Agreement and addressed
to the attention of the President, or at such other address or facsimile number
as the Company shall have furnished to the Investors.

                                      -10-

<PAGE>

     Each such notice or other communication shall for all purposes of this
Agreement be treated as effective or having been given when delivered if
delivered personally, or, if sent by mail, at the earlier of its receipt or
seventy-two (72) hours after the same has been deposited in a regularly
maintained receptacle for the deposit of the mail, addressed and mailed as
aforesaid or, if sent by confirmed facsimile, upon confirmation of facsimile
transfer.

     7.3 GOVERNING LAW. This Agreement shall be governed in all respects by the
internal laws of Japan as applied to agreements entered into among Japanese
residents to be performed entirely within Japan, without regard to principles of
conflicts of law.

     7.4 EXPENSES. The Company and the Investors shall each pay their own
expenses in connection with the transactions contemplated by this Agreement.

     7.5 SURVIVAL. The representations, warranties, covenants and agreements
made in this Agreement shall survive any investigation made by any party hereto
and the closing of the transactions contemplated hereby.

     7.6 SUCCESSORS AND ASSIGNS. This Agreement, and any and all rights, duties
and obligations hereunder, shall not be assigned, transferred, delegated or
sublicensed by any Investor without the prior written consent of the Company.
Any attempt by an Investor without such permission to assign, transfer, delegate
or sublicense any rights, duties or obligations that arise under this Agreement
shall be void. Subject to the foregoing and except as otherwise provided herein,
the provisions of this Agreement shall inure to the benefit of, and be binding
upon, the successors, assigns, heirs, executors and administrators of the
parties.

     7.7 ENTIRE AGREEMENT. This Agreement, the other agreements referenced or
contemplated herein, and the exhibits and schedules hereto and thereto
constitute the full and entire understanding and agreement between the parties
with regard to the subjects hereof and thereof, and no party shall be liable or
bound to any other party in any manner with regard to the subjects hereof or
thereof by any warranties, representations or covenants except as specifically
set forth herein or therein.

     7.8 DELAYS OR OMISSIONS. Except as expressly provided herein, no delay or
omission to exercise any right, power or remedy accruing to any party to this
Agreement upon any breach or default of any other party under this Agreement
shall impair any such right, power or remedy of such non-defaulting party, nor
shall it be construed to be a waiver of any such breach or default, or an
acquiescence therein, or of any similar breach or default thereafter occurring,
nor shall any waiver of any single breach or default be deemed a waiver of any
other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any party of any
breach or default under this Agreement, or any waiver on the part of any party
of any provisions or conditions of this Agreement, must be in writing and shall
be effective only to the extent specifically set forth in such writing. All
remedies, either under this Agreement or by law or otherwise afforded to any
party to this Agreement, shall be cumulative and not alternative.

                                      -11-

<PAGE>

     7.9 SEVERABILITY. Unless otherwise expressly provided herein, the rights of
the Investors hereunder are several rights, not rights jointly held with any of
the other Investors. In the event that any provision of this Agreement becomes
or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Agreement shall continue in full force and effect without said
provision, and the parties agree to negotiate, in good faith, a legal and
enforceable substitute provision which most nearly effects the parties' intent
in entering into this Agreement.

     7.10 TITLES AND SUBTITLES. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or
interpreting this Agreement. All references in this Agreement to sections,
paragraphs, exhibits and schedules shall, unless otherwise provided, refer to
sections and paragraphs hereof and exhibits and schedules attached hereto.

     7.11 COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be enforceable against the parties actually
executing such counterparts, and all of which together shall constitute one
instrument.

     7.12 FACSIMILE EXECUTION AND DELIVERY. A facsimile, telecopy or other
reproduction of this Agreement may be executed by one or more parties hereto,
and an executed copy of this Agreement may be delivered by one or more parties
hereto by facsimile or similar electronic transmission device pursuant to which
the signature of or on behalf of such party can be seen, and such execution and
delivery shall be considered valid, binding and effective for all purposes. At
the request of any party hereto, all parties hereto agree to execute an original
of this Agreement as well as any facsimile, telecopy or other reproduction
hereof.

     7.13 JURISDICTION; VENUE. All disputes or claims arising under or relating
to this Agreement shall be settled by the parties amicably through good faith
discussions upon the written request of any party. In the event that any such
dispute or claim arising under or relating to this Agreement cannot be resolved
thereby within a period of sixty (60) days after such notice has been given,
such dispute or claim shall be subject to the exclusive jurisdiction of the
Tokyo District Court.

     7.14 FURTHER ASSURANCES. Each party hereto agrees to execute and deliver,
by the proper exercise of its corporate, limited liability company, partnership
or other powers, all such other and additional instruments and documents and do
all such other acts and things as may be necessary to more fully effectuate this
Agreement.

            (The remainder of this page is left intentionally blank.)

                                      -12-

<PAGE>

     IN WITNESS WHEREOF, this Agreement is executed as of the date first written
above.

                                        COMPANY:

                                        THIRD WAVE TECHNOLOGIES JAPAN, K.K.

                                        By: /s/ Ivan Trifunovich
                                            ------------------------------------
                                        Name: Ivan Trifunovich
                                        Title: Director

                                        INVESTORS:

                                        MITSUBISHI CORPORATION

                                        By: /s/ Tsunehiko Yanagihara
                                            ------------------------------------
                                        Name: Tsunehiko Yanagihara
                                        Title: General Manager,
                                               Life Sciences Business Unit

                                        CSK INSTITUTE FOR SUSTAINABILITY, LTD.

                                        By: /s/ Masahiro Aozono
                                            ------------------------------------
                                        Name: Masahiro Aozono
                                        Title: President & CEO

   (SIGNATURE PAGE TO SERIES A PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT)

<PAGE>

                                    EXHIBIT A

                              SCHEDULE OF INVESTORS

<TABLE>
<CAPTION>
                                                                  PURCHASE PRICE PER
                                          NUMBER OF   NUMBER OF    SHARE AND WARRANT
                                           SERIES A    WARRANT    EXERCISE PRICE PER
                INVESTOR                    SHARES      SHARES           SHARE
                --------                  ---------   ---------   ------------------
<S>                                       <C>         <C>         <C>
Mitsubishi Corporation                      6,667       1,149           Y71,996
6-3 Marunouchi 2-chome
Chiyoda-ku
Tokyo 100-8086
Japan
(Fax) +81-3-3210-5223
Tsunehiko.yanagihara@mitsubishicorp.com

CSK Institute for Sustainability, LTD.      1,389         239           Y71,996
CSK Aoyama Building
2-26-1
Minami-Aoyama
Minato-ku
Tokyo 107-0062
Japan
(Fax) +81-3-6438-4120
cskis@csk.com
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]